Literature DB >> 8600765

Evaluation of commercial enzyme immunoassay (EIA) and immunofluorescent antibody (FA) test kits for detection of Cryptosporidium oocysts of species other than Cryptosporidium parvum.

T K Graczyk1, M R Cranfield, R Fayer.   

Abstract

A commercial enzyme immunoassay (EIA) (ProSpect Rapid Assay), a direct immunofluorescence antibody (IFA) test for stool testing (MERIFLUOR Cryptosporidium/Giardia), and an indirect IFA test for environmental testing (Hydrofluor-Combo Cryptosporidium/Giardia) were evaluated for detection of low public health risk Cryptosporidium oocyst isolates, and for C. parvum oocyst isolates from human and bovine feces that represent a high public health risk. There was no cross-reactivity of EIA with ova of eight medically important helminths, three Eimeria species oocysts, Sarcocystis cruzi sporocysts, and two Candida sp. isolates. All nine snake oocyst isolates (C. serpentis), two of seven lizard oocyst isolates, one turtle oocyst isolate, two avian oocyst isolates (turkey, C. meleagridis), one C. wrairi oocyst isolate from guinea pigs, one C. muris oocyst isolate from hyrax, one heifer C. muris isolate, and two C. muris-like oocyst isolates from a camel were positive by both IFA tests; six of these 19 oocyst isolates were EIA-positive. There was no difference in the sensitivity and specificity between direct and indirect IFA tests. The sensitivity of the EIA and both IFA tests to the C. parvum oocysts was 100%. The EIA showed less cross-reactivity with the non-C. parvum oocysts (24%) than direct or indirect IFA (76%), and was less sensitive to those isolates (20%) than both IFA tests (63%). A simulated sampling model for high and low public health risk Cryptosporidium oocysts showed that the low risk oocyst isolates may constitute up to 35% of all positive environmental samples by direct or indirect IFA determination, and up to 12% of all EIA positive samples. This study indicates a superiority of direct and indirect IFA and EIA for screening of human-or-bovine-origin fecal specimens, whereas testing of environmental samples may lead to misidentification of medically important isolates. The results demonstrated that the EIA kit can more accurately identify environmental samples containing oocytes pathogenic for humans than both IFA tests. The specificity of commercially available diagnostic kits to C. parvum should be critically examined for cross-species identification before they are recommended or adopted for use in testing environmental samples.

Entities:  

Mesh:

Year:  1996        PMID: 8600765     DOI: 10.4269/ajtmh.1996.54.274

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  19 in total

1.  Morphologic, host specificity, and molecular characterization of a Hungarian Cryptosporidium meleagridis isolate.

Authors:  T Sréter; G Kovács; A J da Silva; N J Pieniazek; Z Széll; M Dobos-Kovács; K Márialigeti; I Varga
Journal:  Appl Environ Microbiol       Date:  2000-02       Impact factor: 4.792

2.  Prevalence of and associated risk factors for shedding Cryptosporidium parvum oocysts and Giardia cysts within feral pig populations in California.

Authors:  E R Atwill; R A Sweitzer; M G Pereira; I A Gardner; D Van Vuren; W M Boyce
Journal:  Appl Environ Microbiol       Date:  1997-10       Impact factor: 4.792

3.  Quantitative assessment of viable Cryptosporidium parvum load in commercial oysters (Crassostrea virginica) in the Chesapeake Bay.

Authors:  Thaddeus K Graczyk; Earl J Lewis; Gregory Glass; Alexandre J Dasilva; Leena Tamang; Autumn S Girouard; Frank C Curriero
Journal:  Parasitol Res       Date:  2006-08-08       Impact factor: 2.289

4.  Distribution of cryptosporidium genotypes in storm event water samples from three watersheds in New York.

Authors:  Jianlin Jiang; Kerri A Alderisio; Lihua Xiao
Journal:  Appl Environ Microbiol       Date:  2005-08       Impact factor: 4.792

5.  Cloning and expression of a DNA sequence encoding a 41-kilodalton Cryptosporidium parvum oocyst wall protein.

Authors:  M C Jenkins; J Trout; C Murphy; J A Harp; J Higgins; W Wergin; R Fayer
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

6.  Failure to differentiate Cryptosporidium parvum from C. meleagridis based on PCR amplification of eight DNA sequences.

Authors:  D Champliaud; P Gobet; M Naciri; O Vagner; J Lopez; J C Buisson; I Varga; G Harly; R Mancassola; A Bonnin
Journal:  Appl Environ Microbiol       Date:  1998-04       Impact factor: 4.792

7.  Molecular analysis of the 18S rRNA gene of Cryptosporidium serpentis in a wild-caught corn snake (Elaphe guttata guttata) and a five-species restriction fragment length polymorphism- based assay that can additionally discern C. parvum from C. wrairi.

Authors:  L M Kimbell; D L Miller; W Chavez; N Altman
Journal:  Appl Environ Microbiol       Date:  1999-12       Impact factor: 4.792

8.  Potential Role of the Eastern Oyster, Crassostrea virginica, in the Epidemiology of Cryptosporidium parvum.

Authors:  R Fayer; C A Farley; E J Lewis; J M Trout; T K Graczyk
Journal:  Appl Environ Microbiol       Date:  1997-05       Impact factor: 4.792

9.  In Vitro Interactions of Asian Freshwater Clam (Corbicula fluminea) Hemocytes and Cryptosporidium parvum Oocysts.

Authors:  T K Graczyk; R Fayer; M R Cranfield; D B Conn
Journal:  Appl Environ Microbiol       Date:  1997-07       Impact factor: 4.792

Review 10.  Clinical significance of enteric protozoa in the immunosuppressed human population.

Authors:  D Stark; J L N Barratt; S van Hal; D Marriott; J Harkness; J T Ellis
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.